CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance

PartnershipACT-101Positive
AI Analysis

Summary

Aptar Pharma will support Aceso's development of ACT-101, an inhaled cystic fibrosis candidate designed to intervene earlier than current CF modulators.

Importance:5/10
Sentiment:
0.60
cystic fibrosisinhaled therapypartnershipdrug modulator

Read the original article

Published by Pharmaceutical Technology on September 7, 2026 2:38 PM

Read Original